Novartis, CH0012005267

Novartis raises 2026 profit outlook. Novartis stock gains 1.89 percent.

Published on 10/27/2026 at 16:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales rose 4.00 percent to USD 14.52 billion for July-September. Novartis stock costs EUR 139.69 on October 27, 2026, up 1.89 percent versus Xetra close.

Guidance and results

On October 27, 2026, Novartis raised 2026 core operating income guidance from a low-single-digit decline to low-single-digit growth.
Third-quarter sales rose 4.00 percent to USD 14.52 billion, while core operating income increased 11.00 percent to USD 6.04 billion.
Novartis stock costs EUR 139.69 at Lang & Schwarz on October 27, 2026 at 4:41 p.m. CET, 1.89 percent above the Xetra close of October 26, 2026.
Bernstein maintained a Hold rating and set a CHF 132.84 target on October 27, 2026.

Novartis, CH0012005267, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) raised its full-year 2026 core operating income outlook on October 27, 2026, moving it from a low-single-digit decline to a range from unchanged to low-single-digit growth, according to Novartis. The stock was trading at EUR 139.69 at Lang & Schwarz on October 27, 2026 at 4:41 p.m. CET, 1.89 percent above the Xetra close of October 26, 2026 at EUR 137.10.

Sales growth supports the outlook

Third-quarter net sales rose 4.00 percent year over year to USD 14.52 billion, while core operating income increased 11.00 percent to USD 6.04 billion. Core operating income margin reached 41.60 percent, an increase of 2.30 percentage points, according to Morningstar.

The sales result was accompanied by a sharp decline in reported profitability. Third-quarter net profit fell to USD 1.20 billion from USD 3.93 billion a year earlier, while the company booked a USD 1.90 billion write-down linked to the del-desiran asset, Morningstar reported on October 27, 2026.

What does the guidance change mean?

The revised outlook changes the direction of the core operating income forecast, but it leaves full-year sales guidance at low-single-digit growth. That distinction matters because the third-quarter core margin expanded even as generic competition reduced sales by 9.00 percentage points, according to the company release dated October 27, 2026.

Analyst target remains a separate signal

Bernstein analyst Justin Smith maintained a Hold rating and set a CHF 132.84 price target for Novartis on October 27, 2026, according to Markets Insider. The target is stated in Swiss francs and is therefore separate from the euro quotation in Germany.

Price holds above the Xetra close

For German investors, the key market figure is the 1.89 percent premium to the EUR 137.10 Xetra close. The move places the euro quotation above the previous German-session base while the earnings picture splits between stronger core performance and the del-desiran impairment.

Novartis was trading at EUR 139.69 at Lang & Schwarz on October 27, 2026 at 4:41 p.m. CET, 1.89 percent above the Xetra close of October 26, 2026 at EUR 137.10. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.